Limits...
Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.

Jin X, Jiang YZ, Chen S, Yu KD, Shao ZM, Di GH - Oncotarget (2015)

Bottom Line: The loss of HR positivity was an independent prognostic factor for worse disease-free survival (DFS) and worse overall survival (OS) in multivariate survival analysis.Furthermore, the switch to the TN phenotype after NCT was another independent prognostic factor for worse survival for both DFS and OS.The loss of HR positivity and the switch to the TN phenotype after NCT were associated with a worse patient outcome.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

ABSTRACT
The hormone receptor (HR) status and human epidermal growth hormone receptor 2 (HER2) status of patients with breast cancer may change following neoadjuvant chemotherapy (NCT). This prospective observational study aimed to evaluate the prognostic impact of receptor conversion in breast cancer patients treated with NCT.Of the 423 consecutive patients who had residual disease in the breast after NCT, 55 (13.0%) changed from HR (+) to HR (-), 23 (5.4%) changed from HR (-) to HR (+), 27 (6.4%) changed from HER2 (+) to HER2 (-), and 13 (3.1%) changed from HER2 (-) to HER2 (+). A total of 54 (12.8%) changed to the triple-negative (TN) tumor phenotype. The loss of HR positivity was an independent prognostic factor for worse disease-free survival (DFS) and worse overall survival (OS) in multivariate survival analysis. Furthermore, the switch to the TN phenotype after NCT was another independent prognostic factor for worse survival for both DFS and OS. In conclusion, patients with breast cancer may experience changes in HR status, HER2 status and tumor phenotype after NCT. The loss of HR positivity and the switch to the TN phenotype after NCT were associated with a worse patient outcome.

No MeSH data available.


Related in: MedlinePlus

Kaplan–Meier estimates of disease-free survival (DFS) and overall survival (OS) according to receptor conversions(a) DFS for hormone receptor (HR) conversion (log-rank test: P < 0.001), (b) DFS for human epidermal growth factor receptor 2 (HER2) conversion (log-rank test: P < 0.001), (c) OS for HR conversion (log-rank test: P < 0.001), (d) OS for HER2 conversion (log-rank test: P = 0.007).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496242&req=5

Figure 2: Kaplan–Meier estimates of disease-free survival (DFS) and overall survival (OS) according to receptor conversions(a) DFS for hormone receptor (HR) conversion (log-rank test: P < 0.001), (b) DFS for human epidermal growth factor receptor 2 (HER2) conversion (log-rank test: P < 0.001), (c) OS for HR conversion (log-rank test: P < 0.001), (d) OS for HER2 conversion (log-rank test: P = 0.007).

Mentions: Kaplan–Meier plots for disease-free survival (DFS) and overall survival (OS) according to HR conversion and HER2 conversion are shown in Figure 2. Patients showing a change in their HR status from (+) to (−) after NCT had significantly worse DFS than the other three groups of patients (P < 0.001) (Figure 2a). Similar significant differences in OS were also observed (P < 0.001) (Figure 2b). According to the four HER2 conversion groups, patients who remained HER2 (−) after NCT had better DFS (P < 0.001) (Figure 2c) and OS (P = 0.007) (Figure 2d).


Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.

Jin X, Jiang YZ, Chen S, Yu KD, Shao ZM, Di GH - Oncotarget (2015)

Kaplan–Meier estimates of disease-free survival (DFS) and overall survival (OS) according to receptor conversions(a) DFS for hormone receptor (HR) conversion (log-rank test: P < 0.001), (b) DFS for human epidermal growth factor receptor 2 (HER2) conversion (log-rank test: P < 0.001), (c) OS for HR conversion (log-rank test: P < 0.001), (d) OS for HER2 conversion (log-rank test: P = 0.007).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496242&req=5

Figure 2: Kaplan–Meier estimates of disease-free survival (DFS) and overall survival (OS) according to receptor conversions(a) DFS for hormone receptor (HR) conversion (log-rank test: P < 0.001), (b) DFS for human epidermal growth factor receptor 2 (HER2) conversion (log-rank test: P < 0.001), (c) OS for HR conversion (log-rank test: P < 0.001), (d) OS for HER2 conversion (log-rank test: P = 0.007).
Mentions: Kaplan–Meier plots for disease-free survival (DFS) and overall survival (OS) according to HR conversion and HER2 conversion are shown in Figure 2. Patients showing a change in their HR status from (+) to (−) after NCT had significantly worse DFS than the other three groups of patients (P < 0.001) (Figure 2a). Similar significant differences in OS were also observed (P < 0.001) (Figure 2b). According to the four HER2 conversion groups, patients who remained HER2 (−) after NCT had better DFS (P < 0.001) (Figure 2c) and OS (P = 0.007) (Figure 2d).

Bottom Line: The loss of HR positivity was an independent prognostic factor for worse disease-free survival (DFS) and worse overall survival (OS) in multivariate survival analysis.Furthermore, the switch to the TN phenotype after NCT was another independent prognostic factor for worse survival for both DFS and OS.The loss of HR positivity and the switch to the TN phenotype after NCT were associated with a worse patient outcome.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

ABSTRACT
The hormone receptor (HR) status and human epidermal growth hormone receptor 2 (HER2) status of patients with breast cancer may change following neoadjuvant chemotherapy (NCT). This prospective observational study aimed to evaluate the prognostic impact of receptor conversion in breast cancer patients treated with NCT.Of the 423 consecutive patients who had residual disease in the breast after NCT, 55 (13.0%) changed from HR (+) to HR (-), 23 (5.4%) changed from HR (-) to HR (+), 27 (6.4%) changed from HER2 (+) to HER2 (-), and 13 (3.1%) changed from HER2 (-) to HER2 (+). A total of 54 (12.8%) changed to the triple-negative (TN) tumor phenotype. The loss of HR positivity was an independent prognostic factor for worse disease-free survival (DFS) and worse overall survival (OS) in multivariate survival analysis. Furthermore, the switch to the TN phenotype after NCT was another independent prognostic factor for worse survival for both DFS and OS. In conclusion, patients with breast cancer may experience changes in HR status, HER2 status and tumor phenotype after NCT. The loss of HR positivity and the switch to the TN phenotype after NCT were associated with a worse patient outcome.

No MeSH data available.


Related in: MedlinePlus